{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:23:26Z","timestamp":1782221006155,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.diabres.2020.108620","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T02:03:56Z","timestamp":1607825036000},"page":"108620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type\u00a0lipodystrophy"],"prefix":"10.1016","volume":"172","author":[{"given":"Anjul","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond E.","family":"Bourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart G.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diabres.2020.108620_b0005","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2020.108620_b0010","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2020.108620_b0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cen.13732","article-title":"Renal complications of lipodystrophy: a closer look at the natural history of kidney disease","volume":"89","author":"Akinci","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.diabres.2020.108620_b0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.diabres.2020.108620_b0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/labinvest.2016.42","article-title":"Effects of combination PPARgamma agonist and angiotensin receptor blocker on glomerulosclerosis","volume":"96","author":"Matsushita","year":"2016","journal-title":"Lab Invest"},{"key":"10.1016\/j.diabres.2020.108620_b0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.12659\/MSM.913461","article-title":"Renal-protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in ob\/ob mice","volume":"25","author":"Li","year":"2019","journal-title":"Med Sci Monit"},{"issue":"25","key":"10.1016\/j.diabres.2020.108620_b0035","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'Agati","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2020.108620_b0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108620_b0045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.diabres.2020.108620_b0050","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.diabres.2020.108620_b0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"10166","key":"10.1016\/j.diabres.2020.108620_b0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.diabres.2020.108620_b0065","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/sj.ki.5000336","article-title":"Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis","volume":"69","author":"Yang","year":"2006","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.diabres.2020.108620_b0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/0886022X.2012.691066","article-title":"Protective effects of PPARgamma agonist in glomerulosclerosis rats induced by adriamycin","volume":"34","author":"Zhou","year":"2012","journal-title":"Ren Fail"},{"issue":"12","key":"10.1016\/j.diabres.2020.108620_b0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.ki.5002248","article-title":"PPAR-gamma agonist protects podocytes from injury","volume":"71","author":"Kanjanabuch","year":"2007","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.diabres.2020.108620_b0080","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.21.12.2135","article-title":"Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy","volume":"21","author":"Imano","year":"1998","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2020.108620_b0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.diabres.2020.108620_b0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720308779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720308779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:14:19Z","timestamp":1759173259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720308779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"alternative-id":["S0168822720308779"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108620","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type\u00a0lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108620"}}